PL3058371T3 - Zastosowanie akamprozatu do modulowania aktywacji erk 1-2 w modelach zwierzęcych dla fxs i asd oraz u osób z rozpoznaniem fxs i asd - Google Patents
Zastosowanie akamprozatu do modulowania aktywacji erk 1-2 w modelach zwierzęcych dla fxs i asd oraz u osób z rozpoznaniem fxs i asdInfo
- Publication number
- PL3058371T3 PL3058371T3 PL14854852T PL14854852T PL3058371T3 PL 3058371 T3 PL3058371 T3 PL 3058371T3 PL 14854852 T PL14854852 T PL 14854852T PL 14854852 T PL14854852 T PL 14854852T PL 3058371 T3 PL3058371 T3 PL 3058371T3
- Authority
- PL
- Poland
- Prior art keywords
- fxs
- asd
- acamprosate
- activation
- animal models
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/48—Nerve growth factor [NGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361890756P | 2013-10-14 | 2013-10-14 | |
| EP14854852.2A EP3058371B1 (en) | 2013-10-14 | 2014-10-14 | Use of acamprosate to modulate erk 1-2 activation in animal models for fxs and asd and individuals diagnosed with fxs and asd |
| PCT/US2014/060527 WO2015057736A1 (en) | 2013-10-14 | 2014-10-14 | Use of acamprosate to modulate erk 1-2 activation in animal models for fxs and asd and individuals diagnosed with fxs and asd |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3058371T3 true PL3058371T3 (pl) | 2021-11-08 |
Family
ID=52828619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14854852T PL3058371T3 (pl) | 2013-10-14 | 2014-10-14 | Zastosowanie akamprozatu do modulowania aktywacji erk 1-2 w modelach zwierzęcych dla fxs i asd oraz u osób z rozpoznaniem fxs i asd |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10634677B2 (pl) |
| EP (1) | EP3058371B1 (pl) |
| JP (1) | JP6637414B2 (pl) |
| AU (1) | AU2014337504B2 (pl) |
| CA (1) | CA2926645C (pl) |
| DK (1) | DK3058371T3 (pl) |
| HU (1) | HUE056551T2 (pl) |
| PL (1) | PL3058371T3 (pl) |
| PT (1) | PT3058371T (pl) |
| RU (1) | RU2696481C2 (pl) |
| WO (1) | WO2015057736A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE056551T2 (hu) | 2013-10-14 | 2022-02-28 | Univ Indiana Res & Tech Corp | Az akamprozát alkalmazása az ERK 1-2 aktiváció modulálására az FXS és az ASD állati modelljeiben, valamint az FXS és ASD diagnózissal rendelkezõ egyéneken |
| WO2017147044A1 (en) * | 2016-02-22 | 2017-08-31 | Indiana University Research And Technology Corporation | Peptides and methods for treatment of neurodegenerative diseases |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6316635B1 (en) * | 1995-06-07 | 2001-11-13 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| NZ324615A (en) | 1996-03-11 | 2000-08-25 | Lilly Co Eli | Method for treating autism using olanzapine |
| US6593133B1 (en) | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
| CN1311818A (zh) | 1998-07-06 | 2001-09-05 | 恩斯吉恩有限公司 | 神经营养因子 |
| AU781218B2 (en) | 1999-08-16 | 2005-05-12 | Revaax Pharmaceuticals, Llc | Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases |
| SE0300586L (sv) | 2003-03-04 | 2004-09-05 | Forskarpatent I Syd Ab | Diagnos av autism |
| PL3305776T3 (pl) | 2004-05-14 | 2020-03-31 | Vertex Pharmaceuticals Incorporated | Związki pirolowe jako inhibitory kinaz białkowych erk i kompozycje farmaceutyczne zawierające te związki |
| US7595167B2 (en) * | 2005-10-11 | 2009-09-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio |
| WO2008060375A2 (en) | 2006-10-06 | 2008-05-22 | The Regents Of The University Of Californina | Upregulating bdnf levels to mitigate mental retardation |
| JP2010510314A (ja) * | 2006-11-22 | 2010-04-02 | シーサイド セラピューティクス，エルエルシー | 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法 |
| NZ577436A (en) | 2006-12-22 | 2012-05-25 | Genentech Inc | Death receptor 6 (dr6) antagonist inhibiting the binding of dr6 to amyloid precursor protein (app), and uses thereof in treating neurological disorders |
| WO2008112772A2 (en) | 2007-03-14 | 2008-09-18 | Baylor Research Institute | Gene expression in peripheral blood mononuclear cells from children with diabetes |
| WO2009033079A1 (en) * | 2007-09-07 | 2009-03-12 | Xenoport, Inc. | Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| US20090239888A1 (en) * | 2008-02-12 | 2009-09-24 | Wisconsin Alumni Research Foundation | Methods for Inhibiting Amyloid Precursor Protein and Beta-Amyloid Production and Accumulation |
| WO2010008995A2 (en) * | 2008-07-14 | 2010-01-21 | Otonomy, Inc. | Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders |
| SI2395990T1 (sl) | 2009-02-12 | 2015-04-30 | Indiana University Research And Technology Corporation Offic Of Technology Transfer | Snov in postopki za zdravljenje razvojne motnje, vključno s komorbidnim in idiopatskim avtizmom |
| US8008539B1 (en) | 2009-03-19 | 2011-08-30 | University Of South Florida | Generation of transgenic human soluble amyloid precursor protein alpha expressing mice |
| BR112012027816A2 (pt) * | 2010-04-30 | 2017-08-08 | Novartis Ag | marcadores preditivos úteis no tratamento da síndrome do x frágil (fxs). |
| US20110294879A1 (en) * | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| WO2012024630A1 (en) | 2010-08-19 | 2012-02-23 | Blanchette Rockefeller Neurosciences Institute | Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators |
| RU2465273C2 (ru) | 2010-08-31 | 2012-10-27 | Общество С Ограниченной Ответственностью "Биофарм-Меморейн" | ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| DK2875355T3 (da) | 2012-07-22 | 2020-03-02 | Univ Indiana Res & Tech Corp | Modulation af sapp-, sapp-alpha- og bdnf-niveauer hos individeer diagnosticeret med fxs og asd |
| HUE056551T2 (hu) | 2013-10-14 | 2022-02-28 | Univ Indiana Res & Tech Corp | Az akamprozát alkalmazása az ERK 1-2 aktiváció modulálására az FXS és az ASD állati modelljeiben, valamint az FXS és ASD diagnózissal rendelkezõ egyéneken |
-
2014
- 2014-10-14 HU HUE14854852A patent/HUE056551T2/hu unknown
- 2014-10-14 AU AU2014337504A patent/AU2014337504B2/en active Active
- 2014-10-14 PL PL14854852T patent/PL3058371T3/pl unknown
- 2014-10-14 US US15/029,596 patent/US10634677B2/en active Active
- 2014-10-14 JP JP2016522755A patent/JP6637414B2/ja active Active
- 2014-10-14 CA CA2926645A patent/CA2926645C/en active Active
- 2014-10-14 WO PCT/US2014/060527 patent/WO2015057736A1/en active Application Filing
- 2014-10-14 PT PT148548522T patent/PT3058371T/pt unknown
- 2014-10-14 RU RU2016118551A patent/RU2696481C2/ru active
- 2014-10-14 DK DK14854852.2T patent/DK3058371T3/da active
- 2014-10-14 EP EP14854852.2A patent/EP3058371B1/en active Active
-
2020
- 2020-03-13 US US16/818,854 patent/US11733243B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016118551A3 (pl) | 2018-07-24 |
| US11733243B2 (en) | 2023-08-22 |
| EP3058371A4 (en) | 2017-04-19 |
| PT3058371T (pt) | 2021-07-26 |
| RU2016118551A (ru) | 2017-11-21 |
| CA2926645A1 (en) | 2015-04-23 |
| CA2926645C (en) | 2022-10-25 |
| JP6637414B2 (ja) | 2020-01-29 |
| HUE056551T2 (hu) | 2022-02-28 |
| WO2015057736A1 (en) | 2015-04-23 |
| DK3058371T3 (da) | 2021-08-02 |
| JP2016536293A (ja) | 2016-11-24 |
| EP3058371A1 (en) | 2016-08-24 |
| RU2696481C2 (ru) | 2019-08-02 |
| US20160266120A1 (en) | 2016-09-15 |
| US20200225233A1 (en) | 2020-07-16 |
| EP3058371B1 (en) | 2021-06-16 |
| US10634677B2 (en) | 2020-04-28 |
| AU2014337504B2 (en) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL239961A0 (en) | Useful real-time diagnostic results | |
| HK1208296A1 (en) | Methods and apparatus to determine impressions using distributed demographic information | |
| EP2987106A4 (en) | ACQUIRING AND ANALYZING PHYSIOLOGICAL DATA | |
| EP3031417A4 (en) | Ultrasonic probe and ultrasonic treatment device | |
| EP2981623A4 (en) | SYSTEMS AND METHOD FOR THE ASSESSMENT OF MICROBIOMES AND TREATMENTS THEREOF | |
| EP3010405A4 (en) | Method and device to measure biosignal | |
| SG11201602236SA (en) | Animal models and therapeutic molecules | |
| PL2941195T3 (pl) | Urządzenie do pomiaru analitów w skórze | |
| IL264559A (en) | Methods and reagents for the evaluation of gestational diabetes | |
| GB2525771B (en) | Methods and systems related to electrosurgical wands | |
| EP2914987A4 (en) | DEVICE AND METHOD FOR VISUALIZING FORMING FEATURES | |
| PL3004833T3 (pl) | Ulepszenia związane z pobieraniem próbek | |
| GB2516343B (en) | Improvements in and relating to ophthalmoscopes | |
| IL244590A0 (en) | Anti-epcam antibodies and methods of use | |
| HK1222864A1 (zh) | 的小分子調節劑和其使用方法 | |
| EP2957925A4 (en) | STREAMING STOMOGRAPHIC PROCESS AND STREAMING TOMOGRAPHY DEVICE | |
| SG11201510021TA (en) | Compositions and methods for use in medical diagnosis | |
| HK1219636A1 (zh) | 經改善的皮膚及頭皮診斷裝置及方法 | |
| EP3064161A4 (en) | Ultrasonic probe and ultrasonic treatment device | |
| EP2953899A4 (en) | LANTHANIDE AGGREGATES AND METHODS OF USE | |
| EP3060061A4 (en) | Use of probiotics in meat | |
| EP2979645A4 (en) | ULTRASONIC DIAGNOSTIC DEVICE AND ULTRASONIC DIAGNOSTIC METHOD | |
| EP2992759A4 (en) | ANIMAL MODEL OF ATOPIC DERMATITIS AND USE THEREOF | |
| PT3058371T (pt) | Uso de acamprosato para modular a ativação de erk 1-2 em modelos animais de sxf e tea e indivíduos diagnosticados com sxf e tea | |
| EP3060163A4 (en) | Early determination of pregnancy status in ruminants |